"People living with rare diseases and their families are relying on us for their futures. We're in a position to extend and change the lives of so many people." Sarepta is at the forefront of medical research and drug development, with a focus on genetic medicines to treat rare neuromuscular and central nervous system diseases. Armed with over two decades of experience in the biopharma sector, Ingram plans to lead Sarepta and upend the entire medical system with fresh and innovative ideas. Prior to joining the company three years ago, Ingram served as the president and chief executive officer of Chase Pharmaceuticals which under his leadership developed programs that profoundly improved the symptomatic treatment of Alzheimer's disease patients. Before this, he was the president at Allergan, a Fortune 500 healthcare company. Ingram balances his current role with being a board member at Endo International, Pacific Life, and as the vice-chairman of Nemus Biosciences. 12.